This article is more than 5 years old. Information may no longer be current.
HPV vaccines decreased the risk for variety of HPV–related diseases
Click Here to Manage Email Alerts
The use of HPV vaccines against types 6, 11, 16 and 18 significantly reduced the incidence of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures in adolescents and younger women enrolled in high-coverage HPV vaccination programs.
Researchers studied data from 17,622 women aged 15 to 26 years enrolled in the FUTURE I or FUTURE II trials. Data were from two groups of women: one sexually naive and the other a mixed population of HPV-exposed and HPV-unexposed women (the intention-to-treat group). The sexually naive group was negative to 14 HPV types.
Vaccination was up to 100% effective at decreasing the risk for all high-grade cervical, vulvar and vaginal lesions and genital warts in women who were negative to 14 HPV types.
In the intention-to-treat group, HPV vaccination significantly reduced the risk of all high-grade cervical lesions, with a risk reduction of 19%, and all disease endpoints regardless of causal HPV type. There was a 50.7% risk reduction for precursor lesions to HPV–related vulvar and vaginal cancers and a 62% risk reduction for genital warts.
Additionally, all categories of Pap abnormalities were decreased by 11.3%, cervical definitive therapy by 23%, and procedures for external genital lesions by 28.3%.
“It is anticipated that these reductions will eventually translate into lower rates of cancer of the cervix, vulva and vagina and lower rates of genital warts,” the researchers said. “Ultimately, the population-based impact of HPV vaccines will require longer-term surveillance beyond the present clinical trials.”
For more information:
- Muñoz N. J Natl Cancer Inst. 2010;102:1-15.